LLY
LLY's valuation is historically cheap, fundamentals are above averages and forward estimates point to improving growth and profitability.
LLY vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 37x | 57x | 35% lower-35% |
| PE percentile | 30 | 50 | 40% lower-40% |
| EPS | $29.80 | $9.50 | 214% higher+214% |
| FCF | $20.1B | $3.2B | 525% higher+525% |
| Loading historical comparisons… | |||
LLY’s earnings and cash flow are above their historical averages, while its earnings multiple is lower.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | Strongly improving |
| Forward earnings | Strong growth |
| Forward revenue | Growth |
| Forward profitability | Expanding |
| Analyst coverage | Moderate |
| Estimate dispersion | Moderate |
LLY’s outlook is generally improving, with growth expectations supporting the valuation case.
LLY PE Valuation
This table applies LLY's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
LLY Earnings Per Share
This chart tracks LLY's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
LLY Quarterly Revenue
This chart tracks LLY's quarterly revenue over time and shows how sales are changing from year to year.
LLY Free Cash Flow
This chart tracks LLY's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
LLY Total Shares
This chart tracks changes in LLY's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
LLY Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
LLY PE vs Healthcare Sector
This chart compares LLY's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
LLY Weekly Price
This chart uses LLY's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
LLY Weekly Moving Averages
This chart compares LLY's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
LLY Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.
MRNA
MRNA's valuation appears fair, fundamentals are below averages and the outlook sends mixed signals, though estimates vary widely.
MRNA vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 24x | 28x | 17% lower-17% |
| PE percentile | 71 | 50 | 41% higher+41% |
| EPS | -$7.98 | $3.44 | 332% lower-332% |
| FCF | -$1.2B | $1.7B | 171% lower-171% |
| Loading historical comparisons… | |||
MRNA’s earnings and cash flow are below their historical averages, while its earnings multiple is lower.
MRNA Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | -- |
| Forward earnings | Loss narrowing |
| Forward revenue | Decline |
| Forward profitability | Strongly expanding |
| Analyst coverage | Moderate |
| Estimate dispersion | Wide |
MRNA’s outlook is mixed, with declining sales expectations a concern.
MRNA PE Valuation
This table applies MRNA's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
MRNA Earnings Per Share
This chart tracks MRNA's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
MRNA Quarterly Revenue
This chart tracks MRNA's quarterly revenue over time and shows how sales are changing from year to year.
MRNA Free Cash Flow
This chart tracks MRNA's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
MRNA Total Shares
This chart tracks changes in MRNA's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
MRNA Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
MRNA PE vs Healthcare Sector
This chart compares MRNA's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
MRNA Weekly Price
This chart uses MRNA's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
MRNA Weekly Moving Averages
This chart compares MRNA's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
MRNA Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.